Pre-Revenue Biotech: The 5-Question Framework

Every biotech investor starts by looking at companies with approved drugs and real revenue. But the biggest returns in biotech come from finding the pre-revenue company whose first drug gets approved, and the stock goes from $5 to $80.

The problem: pre-revenue biotechs are the hardest companies to value. There’s no P/E ratio, no revenue growth rate, no EBITDA margin. You’re betting on science. Most of these companies go to zero. Here’s a five-question framework for finding the ones that don’t.

Question 1: Is the Science Credible?

Start with the publications, not the press releases. A peer-reviewed paper in the New England Journal of Medicine, Lancet, JAMA, or Nature Medicine carries weight. A company press release with a cherry-picked endpoint does not.

Check two things. First, does the mechanism of action make biological sense? If a drug targets a pathway that has been validated in human genetics, that’s better than a novel target with no human data. Second, is there genetic validation? Drugs backed by human genetics data have a substantially higher probability of success, because nature already ran the experiment.

Real example: Cogent Biosciences (COGT) pre-bezuclastinib had strong science behind it: the KIT D816V mutation is the driver of systemic mastocytosis, and bezuclastinib was designed to hit that target. The Phase 2 data confirmed what the biology predicted. Cogent was a pre-revenue company with a drug that made sense. For the full PDUFA story, see the COGT bezuclastinib GIST primer.

Red flag: The company has no peer-reviewed publications, only conference abstracts and press releases.

Question 2: Is the Market Real?

A disease with 500 patients and no approved therapy is a better bet than a disease with 5 million patients and entrenched competition. The “better than nothing” advantage is real.

Ask three sub-questions. How many patients actually have this disease? What do doctors prescribe today? Is there a standard of care, and does this drug beat it?

An ultra-rare disease with a clear unmet need gives you pricing power and a faster path to approval, because the FDA applies a different risk-benefit calculus when there’s no alternative. But the market is small. A drug for 2,000 patients at $400,000 per year generates $800 million in peak sales. That’s $800 million in peak sales for a rare disease, but it’s also the ceiling.

Real example: Savara (SVRA) pre-MOLBREEVI targeted autoimmune pulmonary alveolar proteinosis (aPAP), a disease with no approved therapy and roughly 3,000 patients in the U.S. The Phase 3 data was published in NEJM, and the FDA granted Priority Review. Pre-revenue, one drug, one indication, clear unmet need. See the SVRA MOLBREEVI PDUFA primer for the full regulatory picture.

Question 3: Can They Afford to Get to the Finish Line?

Cash runway is the kill shot for pre-revenue biotechs. Take cash and equivalents from the latest 10-Q, divide by the quarterly burn rate. If the runway is under 18 months, dilution is coming. Under 12 months is a red flag. Under 6 months means avoid.

Some companies get non-dilutive funding: BARDA grants, Gates Foundation grants, royalty financing, or partnership milestones. These extend the runway without issuing shares. A company that can fund Phase 3 with non-dilutive capital is in a fundamentally different position than one that needs a secondary offering.

Check the cash position before you check anything else. A great drug at a company that runs out of money in 10 months is not an investment. It’s a donation. Companies in this position typically raise capital at a 20 to 30% discount to market, and existing shareholders get diluted whether they participate or not.

Question 4: Who Else Is in the Race?

Build a competitive analysis table. Who else is targeting the same indication? What stage are they in? Do they have better data?

Being second to market in a niche indication means splitting a small market. The first mover gets 60 to 70% of the revenue. The second mover fights for scraps. If a competitor has Phase 3 data that’s better than your company’s Phase 2 data, the market has already picked a winner and you’re betting on the loser.

Also check if a Big Pharma company is working on the same target. A large pharma with established commercial infrastructure can launch faster than a pre-revenue biotech, even if the biotech’s data is better. Speed to market matters.

Question 5: What Does Success Look Like?

Estimate peak sales: patient population multiplied by price per patient, multiplied by estimated market share. For a drug treating 50,000 U.S. patients at $100,000 per year with 40% share, that’s $2 billion in peak sales.

Apply the 5x peak sales rule of thumb for a fully derisked biotech: $2 billion in peak sales means the company is worth roughly $10 billion if the drug is approved and launched. Then discount for pre-approval risk. A Phase 3 drug has roughly a 55 to 60% cumulative probability of approval. A Phase 2 drug: under 33%. Your entry price should reflect the probability, not the peak sales dream.

Real example: Capricor (CAPR) pre-deramiocel AdCom. The FDA briefing documents raised questions about the clinical data. The AdCom voted 9-3 against approval. The pre-revenue framework flagged the risk: the science had gaps, the trial data was contested, and the AdCom outcome was foreseeable. For broader valuation context, see the biotech valuation methods guide.

The Final Checklist

Before buying a pre-revenue biotech, run this checklist:

• At least one peer-reviewed publication in a major journal
• Mechanism of action with human genetics or biological validation
• Cash runway above 18 months, or non-dilutive funding in place
• No competitor with better data further along in development
• Peak sales estimate that justifies the current market cap, discounted for pre-approval risk
• Management team with prior biotech experience (not first-time CEO from academia)

If you can’t check all six boxes, you’re not investing. You’re gambling. Most pre-revenue biotechs go to zero. The 5% that don’t look like this: credible science, real market, adequate cash, competitive position, and a valuation that doesn’t assume perfection. For the full investing fundamentals, start with the guide to biotech investing. For understanding how the FDA evaluates drugs at this stage, see the FDA’s drug development and review process.